Glycosaminoglycan Template Disruption Approach
Target: HSPG2
Composite Score: 0.597
Price: $0.60▲50.6%
Citation Quality: Pending
neurodegeneration
Status: proposed
🟢 Parkinson's Disease 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
C+
Composite: 0.597
Top 52% of 1374 hypotheses
T5 Contested
Contradicted by evidence, under dispute
B+
0.70
Top 39%
B
0.65
Top 36%
B+
0.75
Top 35%
B
0.60
Top 44%
B
0.65
Top 54%
B+
0.70
Top 32%
C+
0.55
Top 48%
B+
0.70
Top 39%
B
0.65
Top 43%
B+
0.70
Top 27%
Evidence
3 supporting
|
3 opposing
Citation quality: 100%
Debates
1 session
A+
Avg quality: 0.95
Convergence
1.00
A+
30 related hypothesis share this target
From Analysis:
Protein aggregation cross-seeding across neurodegenerative diseases
What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Transglutaminase-2 Cross-Linking Inhibition Strategy
Score: 0.639 | Target: TGM2
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.584 | Target: TREM2
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.551 | Target: G3BP1
HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
Score: 0.544 | Target: DNAJB6
Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Score: 0.469 | Target: PHB2
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.465 | Target: TARDBP
Description
Heparan sulfate and other glycosaminoglycans serve as nucleation templates that facilitate cross-seeding by concentrating different amyloidogenic proteins and stabilizing cross-β structures. Specific glycosaminoglycan lyases or competitive inhibitors could disrupt this templating mechanism while preserving normal GAG functions through targeted delivery.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["HSPG2 perlecan
extracellular matrix"] --> B["Heparan sulfate chains
polyanionic surface"]
B --> C["Electrostatic attraction
of amyloidogenic proteins"]
C --> D["Alpha-synuclein
monomer binding"]
C --> E["Amyloid-beta
monomer binding"]
C --> F["Tau protein
monomer binding"]
D --> G["Local concentration
micromolar range"]
E --> G
F --> G
G --> H["Nucleation template
0.5-1.0 nm sulfate spacing"]
H --> I["Conformational catalysis
beta-sheet formation"]
I --> J["Cross-beta amyloid
fibril assembly"]
J --> K["Cross-seeding between
different amyloid species"]
K --> L["Synaptic dysfunction
and neuroinflammation"]
L --> M["Progressive neuronal
death and degeneration"]
N["Glycosaminoglycan lyases
targeted delivery"] -->|"disrupts"| H
O["Competitive GAG inhibitors
heparin mimetics"] -->|"blocks"| C
N --> P["Preserved normal
GAG functions"]
O --> P
classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
class A,B,G,H normal
class N,O,P therapeutic
class J,K,L,M pathology
class I outcome
class C,D,E,F molecular
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations
6 with PMID
Validation: 100%
3 supporting / 3 opposing
✓
For
(3)
(3)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 4CLIN 2GENE 0EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 3
Glycosaminoglycans promote aggregation of tau, α-synuclein, and TDP-43
Heparan sulfate facilitates cross-seeding between different amyloid proteins
GAG-targeting therapeutics show promise in proteinopathies
✗ Opposing Evidence 3
GAG degradation can worsen neurodegeneration by disrupting essential signaling pathways
Heparan sulfate may actually protect against some forms of protein aggregation
GAG-targeting therapeutics have shown limited CNS efficacy due to delivery issues
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration
Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
Description: DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.Target: DNAJB6 (DnaJ heat shock protein family member B6)
Supporting Evidence: DNAJB6 pote
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.
Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor
Specific Weaknesses:
- The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43
- No direct evidence that DNAJB6 inhibits cross-seeding between different protein types
- The cited PMIDs don't actually support cross-seeding inhibition claims
- DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
PRACTICAL FEASIBILITY ASSESSMENT
Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor
Druggability: MODERATE-POOR
- Target Class: Heat shock protein co-chaperone (difficult to drug directly)
- Chemical Matter: Limited. No known direct DNAJB6 activators exist
- Existing Tools:
- HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
- Gene therapy vectors for DNAJB6 overexpression (preclinical only)
- Direct competitors: None targeting DNAJB6 specifically
- Adjacent space: Multiple HSP70/HSP90 programs (Orphazy
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
7d Trend
↔
Stable
7d Momentum
▼ 1.0%
Volatility
Low
0.0133
Events (7d)
6
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.484 | ▲ 1.1% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.479 | ▲ 3.1% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.464 | ▼ 1.2% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.470 | ▲ 1.4% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.463 | ▲ 0.3% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.462 | ▼ 0.7% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.465 | ▼ 1.2% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.471 | ▲ 1.5% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.464 | ▼ 17.4% | 2026-04-03 23:46 | |
| 💬 | Debate Round | $0.561 | ▲ 14.9% | market_dynamics | 2026-04-03 09:12 |
| 📊 | Score Update | $0.488 | ▼ 8.9% | market_dynamics | 2026-04-03 08:32 |
| 💬 | Debate Round | $0.536 | ▲ 13.7% | market_dynamics | 2026-04-03 07:02 |
| 📄 | New Evidence | $0.472 | ▼ 15.8% | market_dynamics | 2026-04-03 06:57 |
| 📊 | Score Update | $0.561 | ▲ 7.1% | market_dynamics | 2026-04-03 06:24 |
| 📄 | New Evidence | $0.523 | ▼ 19.3% | market_dynamics | 2026-04-03 06:20 |
Clinical Trials (3) Relevance: 25%
0
Active
Active
1
Completed
Completed
0
Total Enrolled
Total Enrolled
Phase 2
Highest Phase
Highest Phase
Untitled Trial
Phase 2
Completed (2002)
·
· Academic
Untitled Trial
Preclinical
Active
·
· Alector/Ionis
Untitled Trial
Preclinical
Completed
·
· Academic
📚 Cited Papers (27)
[WALANT - Wide Awake Local Anaesthesia No Tourniquet: Complications in elective and acute traumatological Hand Surgery Procedures].
Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... (2022) · PMID:35168268
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.
The Journal of biological chemistry (2001) · PMID:11604391
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Author Correction: Distinct effects of social motivation on face evaluations in adolescents with and without autism.
Scientific reports (2018) · PMID:30573750
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Engineering complex communities by directed evolution.
Nature ecology & evolution (2021) · PMID:33986540
9 figures
Extended Data Figure 1.
Non-additive function, costly function, and two empirically motivated functions. (A) Illustration of the different types of community function we have considered. In addition to th...
pmc_api
Extended Data Figure 2.
Alternative ecological scenarios with metabolic cross-feeding. Besides the rich medium without cross-feeding shown in the main text, we have included two other ecological scenarios...
pmc_api
Successful Nonoperative Treatment of Osteochondritis Dissecans of the Humeral Capitellum in a Young Baseball Player with Advanced Skeletal Maturity.
Progress in rehabilitation medicine (2021) · PMID:34825100
4 figures
Fig. 1.
Sonographic image of OCD of the humeral capitellum in the sagittal plane showing irregularity and discontinuity of the subchondral bone.
pmc_api
Fig. 2.
(A) Radiograph taken at the first examination showing an osteochondral lesion on the lateral side of the capitellum and new bone formation along the lateral side of capitellum (arr...
pmc_api
Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.
The Journal of biological chemistry (2001) · PMID:11604391
No extracted figures yet
Electrophysiological studies in a mouse model of Schwartz-Jampel syndrome demonstrate muscle fiber hyperactivity of peripheral nerve origin.
Muscle & nerve (2009) · PMID:19367640
No extracted figures yet
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds.
Proceedings of the National Academy of Sciences of the United States of America (2013) · PMID:23898162
No extracted figures yet
Incidence, Length of Stay, and Prognosis of Hospitalized Patients With Pleural Empyema
Chest (2014) · PMID:24394842
No extracted figures yet
Clinical practice guideline: tonsillitis I. Diagnostics and nonsurgical management.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2016) · PMID:26755048
No extracted figures yet
Midkine is a serum and urinary biomarker for the detection and prognosis of non-small cell lung cancer.
Oncotarget (2016) · PMID:27974680
No extracted figures yet
Combining population genomics and fitness QTLs to identify the genetics of local adaptation in Arabidopsis thaliana.
Proceedings of the National Academy of Sciences of the United States of America (2018) · PMID:29686078
No extracted figures yet
📙 Related Wiki Pages (15)
EED genesleep-disruption-neurodegeneration mechanismAlibaba Tongyi Qianwen-Bio (Chinese Biomedical LLM ai_toolCircadian Rhythm Disruption in Neurodegeneration mechanismGlycosaminoglycan Metabolism Pathway mechanismSleep Disruption in Alzheimer's Disease mechanismCircadian Disruption in Neurodegeneration mechanismSleep Disruption and Alzheimer's Disease — mechani experimentPrion-Like Propagation of Proteinopathies — Templa hypothesisNeurodegeneration diseaseCerebral Amyloid Angiopathy (CAA) diseaseCircadian Rhythm Disruption in Neurodegeneration mechanismNeural Circuit Disruption in Neurodegeneration mechanismSleep and Circadian Disruption in Neurodegeneratio mechanismExtracellular Vesicle and Tunneling Nanotube-Media mechanism
📓 Linked Notebooks (4)
📓 SciDEX Analysis: 2026 04 01 Gap 9137255B
Computational notebook for SDA-2026-04-01-gap-9137255b
📓 Protein aggregation cross-seeding across neurodegenerative diseases — Analysis Notebook
Jupyter notebook for analysis SDA-2026-04-01-gap-9137255b: What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
📓 Protein aggregation cross-seeding across neurodegenerative diseases — Rich Analysis
Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative dise …
📓 Protein aggregation cross-seeding across neurodegenerative diseases
What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
Wiki Pages
EEDgenesleep-disruption-neurodegenerationmechanismAlibaba Tongyi Qianwen-Bio (Chinese Biomedical LLMai_toolCircadian Rhythm Disruption in NeurodegenerationmechanismGlycosaminoglycan Metabolism PathwaymechanismSleep Disruption in Alzheimer's DiseasemechanismCircadian Disruption in NeurodegenerationmechanismSleep Disruption and Alzheimer's Disease — mechaniexperimentPrion-Like Propagation of Proteinopathies — TemplahypothesisNeurodegenerationdiseaseCerebral Amyloid Angiopathy (CAA)diseaseCircadian Rhythm Disruption in NeurodegenerationmechanismNeural Circuit Disruption in NeurodegenerationmechanismSleep and Circadian Disruption in NeurodegeneratiomechanismExtracellular Vesicle and Tunneling Nanotube-Mediamechanism
Dependency Graph (1 upstream, 0 downstream)
Linked Experiments (1)
Related Hypotheses
Glial Glycocalyx Remodeling Therapy
Score: 0.649 | neurodegeneration
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.950 | neurodegeneration
PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
Score: 0.941 | neurodegeneration
Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
Score: 0.933 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
2.0 years
🧪 Falsifiable Predictions (2)
2 total
0 confirmed
0 falsified
If hypothesis is true, intervention disrupt this templating mechanism while preserving normal GAG functions through targeted delivery
pending
conf: 0.65
Expected outcome: disrupt this templating mechanism while preserving normal GAG functions through targeted delivery
Falsified by: Intervention fails to disrupt this templating mechanism while preserving normal GAG functions through targeted delivery
If hypothesis is true, intervention fragment the long HS chains that serve as aggregation templates while generating shorter fragments that compete for amyloid binding without supporting nucleation
pending
conf: 0.65
Expected outcome: fragment the long HS chains that serve as aggregation templates while generating shorter fragments that compete for amyloid binding without supporting nucleation
Falsified by: Intervention fails to fragment the long HS chains that serve as aggregation templates while generating shorter fragments that compete for amyloid binding without supporting nucleation
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
Predicted Protein Structure
🔮 HSPG2 — AlphaFold Prediction P98160 Click to expand 3D viewer
Source Analysis
Protein aggregation cross-seeding across neurodegenerative diseases
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!